Home|Best-Bschool-in-india-2018

DSIJ Mindshare

FIIs Favourite: Caplin Steriles Secures US FDA Approval, FIIs Stake Rises to 4.86 per cent FIIs Favourite: Caplin Steriles Secures US FDA Approval, FIIs Stake Rises to 4.86 per cent

FIIs Favourite: Caplin Steriles Secures US FDA Approval, FIIs Stake Rises to 4.86 per cent

Caplin Point Laboratories has demonstrated robust financial performance in recent quarters. The company reported revenue of Rs 1,523 crore for Q3 FY25, which is equivalent to its full-year revenue in FY23.

Abhishek Wani 0 155 Article rating: 4.7

Caplin Point Laboratories has demonstrated robust financial performance in recent quarters. The company reported revenue of Rs 1,523 crore for Q3 FY25, which is equivalent to its full-year revenue in FY23.

Read more
Sensex & Nifty End Flat, Midcap & Smallcap Indices Down Upto 1.7 Per Cent Sensex & Nifty End Flat, Midcap & Smallcap Indices Down Upto 1.7 Per Cent

Sensex & Nifty End Flat, Midcap & Smallcap Indices Down Upto 1.7 Per Cent

The Nifty 50 ended marginally lower by 0.01 per cent at 22,545.05, and the Sensex inched up by 0.01 per cent to close at 74,612.43.

Manoj Reddy Sama 0 158 Article rating: 1.0

Market breadth was heavily negative, with 571 advances and 2,292 declines, indicating a strong negative sentiment prevailed among investors.

Read more
Shares of this NBFC Soared by 19 per cent After RBI Notification; Earlier the this Micro Finance Organisation Secured USD 50 Million IFC Investment Shares of this NBFC Soared by 19 per cent After RBI Notification; Earlier the this Micro Finance Organisation Secured USD 50 Million IFC Investment

Shares of this NBFC Soared by 19 per cent After RBI Notification; Earlier the this Micro Finance Organisation Secured USD 50 Million IFC Investment

With a market capitalisation of Rs 15,623 crore and a PE ratio of 17.7x, the company trades at a premium compared to the industry PE of 20.1x.

Prajwal Wakhare 0 92 Article rating: 5.0
Read more
RSS
First7576777880828384Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual
BSE Enlistment No. 5307

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual
BSE Enlistment No. 1346

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Conditions | Privacy Statement | WhiteList